Introduction {#s01}
============

In many cell types, nuclei occupy specific subcellular localizations that are functionally important ([@bib28]). In mammalian muscle, nuclei are positioned at the muscle cell periphery in a manner that maximizes internuclear distance. Myonuclear mispositioning is a feature of certain muscle diseases ([@bib45]; [@bib21]), and model organisms that are mutant for genes required to position myonuclei exhibit decreased muscle function ([@bib56]; [@bib18]; [@bib22]; [@bib39]; [@bib46]). These findings argue that correct nuclear positioning is essential for muscle function.

Skeletal muscle development and structure are highly conserved between the fruit fly *Drosophila melanogaster* and humans. In both humans and *Drosophila*, muscle cells are multinucleated and formed from the iterative fusion of muscle precursor cells, each of which contributes a nucleus to the growing myotube. After fusion, myonuclei in each *Drosophila* myotube are present as a single cluster. Subsequently, the myonuclei undergo coordinated movements that ultimately leave them evenly distributed along the length of the muscle cell. The first step of nuclear positioning occurs at stage 14 (10--11 h after egg laying \[AEL\]), when the myonuclei separate into two clearly defined groups along the myotube's long axis. Then, during stages 15 (11--13 h AEL) and 16 (13--16 h AEL), the two clusters of myonuclei migrate away from the myotube's center toward opposite muscle poles. During stage 17 (16--24 h AEL), the last stage of embryonic development, myonuclei spread out from the two clusters and fill in the myofiber evenly, such that the distance between myonuclei is maximized ([@bib39]). Finally, this even spacing is maintained, likely by active mechanisms, during the lifetime of the larval myofibers ([@bib18]; [@bib36]).

The regulation of myonuclear positioning is poorly understood. A key player in the process is Ensconsin (Ens)/MAP7, a microtubule (MT)-associated protein (MAP). Ens promotes Kinesin-based MT transport by relieving Kinesin from its autoinhibited conformation ([@bib4]) or by recruiting Kinesin to MTs ([@bib50]). *ens* loss-of-function mutants exhibit a complete block in myonuclear separation and pole-ward cluster migration through stage 16; at this stage, control myonuclei reside in two clusters near opposite myotube poles, while *ens* mutant myonuclei are present as a single cluster ([@bib39]). Loss of Kinesin heavy chain (Khc) impairs myonuclear movement ([@bib39]), as do mutations in the genes encoding the MT minus end--directed motor protein Dynein heavy chain and the motor protein adaptor Sunday driver ([@bib22], [@bib23]; [@bib46]). Taken together, these findings demonstrate the centrality of MTs and associated proteins to myonuclear positioning. Interestingly, *ens* is the only mutant isolated to date where myonuclear movement appears to be completely blocked. While maternal products may partially ameliorate the phenotypes of *Khc*, *Dhc*, and *syd* zygotic mutants, the uniqueness of the *ens* phenotype raises the possibility that Ens plays additional roles in myonuclear movement beyond its regulation of MT-based transport. Indeed, in other cell types, Ens has been shown to be a MT polymerizing factor ([@bib25]). How Ens promotes nuclear movement in muscle, and what other proteins regulate its critical activity, are outstanding questions in the field.

MT networks, which are essential for myonuclear positioning, undergo dramatic changes during muscle development. In mammalian cell culture, following myoblast fusion, centrosomes are lost and centrosomal proteins relocalize to alternative MT organizing centers (MTOCs) in the acentrosomal myotube, most prominently the myonuclear envelopes ([@bib51]). In *Drosophila*, MTs similarly reorganize during muscle development; starting in the embryonic myotube, most MTs run parallel to the cell's long axis, but by the third-instar stage of larval development, immunofluorescent staining for Tubulin clearly reveals that MT arrays also extend from myonuclear envelopes ([@bib18]; [@bib39]; [@bib36]). Only two genes, *pavarotti* and *RacGAP50C*, have been implicated in the regulation of muscle MT reorganization in the embryo ([@bib27]). Much more needs to be learned about how this transition occurs.

Proteins that regulate MT networks in other cell types are strong candidates for being factors in muscle MT organization and MT-dependent myonuclear positioning. One such factor is the MT minus end--binding protein Ninein, encoded by the gene *NIN*. Pioneering cell culture experiments showed that Ninein localizes to centrosomes ([@bib6]) and noncentrosomal MTOCs ([@bib40]) and that Ninein anchors MTs to MTOCs and promotes MT nucleation by docking γ-Tubulin ([@bib1]; [@bib10]; [@bib17]; [@bib47]). More recently, cell culture studies and RNAi-based in vivo approaches have affirmed critical roles for Ninein in regulating MT organization in numerous cell types. Surprisingly, recently generated null *NIN* mutants in invertebrates are relatively normal: *Caenorhabditis elegans* mutants for the *NIN* orthologue *noca*-1 are sterile with defects in the noncentrosomal MT arrays of the germline and epidermis but have grossly normal morphology and develop to adulthood ([@bib55]). Mutants for the *Drosophila NIN* orthologue *Bsg25D* are viable and fertile ([@bib35]; [@bib57]). Loss of Ninein/NOCA-1 in *C. elegans* is partially compensated for by the MT minus end protein Patronin ([@bib55]); no redundant factors have been identified in *Drosophila*. Since *Bsg25D/Ninein* is conserved from invertebrates to humans, *Bsg25D* may have important functions not readily detectable by single mutant analysis. How does Bsg25D function, and what proteins does it interact with in muscle?

In this work, we find that Bsg25D acts with Ens to regulate myonuclear positioning. Muscle-specific *Bsg25D* overexpression caused myonuclear positioning defects in embryonic myotubes, and overexpression of *Bsg25D* and *ens* reciprocally affected the speed and direction of myonuclear movement. In mature myofibers, overexpressed *Bsg25D* caused nuclear positioning phenotypes, MT defects, and reduced muscle stiffness and function. We conclude that Bsg25D, under wild-type conditions, binds to Ens and promotes its activity in myonuclear positioning, whereas when Bsg25D is expressed at high levels, it alters Ens localization and function, phenocopying *ens* mutants, and ultimately disrupts muscle MT networks and muscle function. Our results shed further light on the function of Ens in the process of nuclear movement and find a novel in vivo role for Bsg25D/Ninein, a poorly understood centrosomal protein, in myonuclear positioning.

Results {#s02}
=======

Bsg25D and Ens interact in vitro and colocalize in embryonic myotubes {#s03}
---------------------------------------------------------------------

We have previously shown that myonuclei in *ens* mutant embryos fail to separate into two clusters and migrate toward muscle poles ([@bib39]). To better understand the mechanisms underlying myonuclear positioning, we performed a yeast two-hybrid screen to identify proteins that interact with Ens. In addition to clones of *Khc*, which we have previously shown to genetically and physically interact with Ens ([@bib39]), we recovered numerous clones corresponding to *Bsg25D*, the *Drosophila* homologue of vertebrate *Ninein* ([@bib35]; [@bib57]). The sequence common to all recovered *Bsg25D* clones (nucleotides 1463--1,577/amino acids 487--526, using isoform Bsg25D-PB as a reference) falls entirely within the gene's fourth exon, which is present in all *Bsg25D* alternatively spliced transcripts; thus, the Ens-binding region is present in all Bsg25D isoforms ([Fig. 1 A](#fig1){ref-type="fig"}). This region is found in the first of two spans of Bsg25D that contain numerous coiled coil domains. The Ens-binding region is nonoverlapping with the region of Bsg25D thought to be necessary for γ-Tubulin binding, based on alignment between Bsg25D and mouse Ninein, where the latter region was experimentally defined ([@bib17]). The Ens-binding region also does not overlap with the N-terminal Bsg25D region (amino acids 1--353) that has been shown to bind MTs in vitro ([@bib35]). The Ens--Bsg25D interaction was validated in S2 cells, where overexpressed Ens and full-length Bsg25D coimmunoprecipitated ([Fig. 1 A](#fig1){ref-type="fig"}).

![**Bsg25D and Ens physically interact and colocalize in myotubes in vivo. (A)** Top: Map of Bsg25D indicating coiled--coil (CC) domain--rich regions and regions that bind Ens (this work), MTs ([@bib35]), and γ-Tubulin (predicted from alignment to mouse Ninein; [@bib17]). In *Bsg25D−*, the entire coding region has been removed and replaced by a mini-white (mini w+) reporter cassette. Bottom: Coimmunoprecipitation of overexpressed Ens-GFP and Bsg25D-HA from S2 cells. The largest Bsg25D-HA band is the main protein species, and smaller bands likely represent cleavage products. IP, immunoprecipitation. **(B)** Bsg25D expression in the stage 16 embryo. Left and right panels are the same image with and without Tropomyosin, a muscle marker. Left: Bsg25D, gray. Right: Bsg25D, magenta; Tropomyosin, green. Red box indicates primordial germ cells. **(C)** Left: Extended focus projection of one stage 16 hemisegment. Right: Orthogonal (YZ) section of indicated (red box) lateral transverse myotube. Crosshairs identify a Bsg25D+ punctum inside myotube. Bsg25D, magenta; Tropomyosin, green. **(D)** Immunofluorescent staining of stage 16 myotube for Bsg25D and Plp. Image is a single slice from a Z-stack. Bsg25D, magenta; Plp, green; colocalization, white (see red arrows). **(E)** Immunofluorescent staining of stage 16 myotube for Bsg25D and Ens. Image is a single slice from a Z-stack. In the merged image, Bsg25D, magenta; Ens, green; colocalization, white (highlighted by arrows). In D and E, images in bottom row are higher magnification views of boxed regions, and dashed lines outline lateral transverse muscles. In all images, scale bars = 5 µm.](JCB_201808176_Fig1){#fig1}

Next, we examined *Bsg25D* expression in vivo. In situ hybridization performed by the Berkeley Drosophila Genome Project showed *Bsg25D* transcripts in embryonic muscle ([@bib52], [@bib53]; [@bib30]). By immunofluorescent antibody staining using an existing antibody against Bsg25D ([@bib32]), we found that Bsg25D protein was present in discrete puncta in numerous cell types in the embryo. (The Bsg25D signal was absent from *Bsg25D* null mutants \[Fig. S1 A\].) This punctate expression pattern was expected, as Bsg25D is known to localize to centrosomes in mononucleated cells ([@bib35]; [@bib57]). Notably, it was most strongly expressed in primordial germ cells, as has been previously observed ([@bib57]; [Fig. 1 B](#fig1){ref-type="fig"}, red outlined box). Combined immunofluorescent labeling of Bsg25D and the muscle marker Tropomyosin showed that from stage 14 to stage 16, the stages during which myonuclei split into two clusters and migrate toward muscle poles, Bsg25D was broadly but weakly expressed in the cytoplasm and strongly enriched in cytoplasmic puncta of myotubes ([Fig. 1 B](#fig1){ref-type="fig"}). Analysis of orthogonal slices of Z-stacks confirmed the presence of Bsg25D puncta inside myotubes ([Fig. 1 C](#fig1){ref-type="fig"}). At stage 16, there were between zero and eight Bsg25D puncta per myotube (mode = 1, mean = 2.1). Puncta were excluded from the nucleus but otherwise had no conspicuous localization. Single puncta were also visible in some unfused myoblasts. We used genetic reporters and antibody staining to determine whether the Bsg25D puncta in myotubes reside in various organelles and subcellular structures. We did not observe Bsg25D colocalization with markers of Golgi apparatus, ER, or endosomes, though we did observe that 95% of Bsg25D puncta were in proximity to Arl8 (*n* = 60 myotube puncta), a protein that localizes to lysosomes ([@bib3]; [@bib31]; Fig. S1 B). Counter to our expectations ([@bib6]; [@bib40]; [@bib35]; [@bib57]), we also failed to detect colocalization between Bsg25D puncta and the MTOC component γ-Tubulin or the MT component α-Tubulin (Fig. S1 B). Interestingly, however, all myotube Bsg25D puncta (*n* = 59) colocalized with the MTOC component Pericentrin-like protein (Plp), the sole *Drosophila* Pericentrin orthologue ([Figs 1 D](#fig1){ref-type="fig"} and S1 C). This finding is consistent with physical interactions observed between their mammalian orthologues in cell culture ([@bib11]).

Since we found that Bsg25D and Ens physically interact in vitro, we performed immunofluorescent antibody staining to determine whether they colocalize in embryonic myotubes. While the bulk of Ens protein localized to MTs, as expected for a MAP (Fig. S1 D), there was also Ens protein present in Bsg25D puncta; thus, Ens and Bsg25D colocalize in cytoplasmic puncta in embryonic myotubes ([Fig. 1 E](#fig1){ref-type="fig"}). Outside of these puncta, the broad, diffuse cytoplasmic Bsg25D signal was difficult to resolve, so it is possible that Bsg25D and Ens are both present in other parts of the cell as well. Since Bsg25D and Ens bind in vitro and colocalize in myotubes, we hypothesized that *Bsg25D* functions with *ens* during myonuclear positioning.

Loss of Bsg25D enhances *ens* myonuclear positioning defects {#s04}
------------------------------------------------------------

To determine whether Bsg25D functions in myonuclear positioning, we generated a null *Bsg25D* mutant. We used an accelerated homologous recombination approach ([@bib2]) to remove the entire *Bsg25D* locus, including all predicted alternatively spliced transcripts ([Fig. 1 A](#fig1){ref-type="fig"} and Materials and methods). Western blotting showed Bsg25D protein was absent from larval lysates ([Fig. 2 A](#fig2){ref-type="fig"} and Materials and methods).

![***Bsg25D*genetically interacts with *ens*, but not *plp*. (A)** Western blot showing loss of Bsg25D protein in *Bsg25D*^−/−^ larval lysates. **(B)** Extended-focus projections of representative stage 16 hemisegments from indicated genotypes. **(C)** Bar graph showing mean nuclear spread and SD. For each genotype, *n* (number of hemisegments) is control, *n* = 39; *Bsg25D*^−/−^, *n* = 61; *ens*^−/+^, *n* = 46; *Bsg25D-/Df;ens*^−/+^, *n* = 43; *Bsg25D;ens*^−/+^, *n* = 71; *Bsg25D*^−/−^*;BAC, ens*^−/+^, *n* = 44. P values were calculated by Student's *t* test. **(D)** Graph showing the percentage of myotubes that have a single nuclear cluster. P values were calculated by Fisher's exact test from contingency tables comparing *ens-/+* to each other genotype. *n* values (number of myotubes for each genotype) are **ens*^−/+^*, 239; *Bsg25D*^−/−^*;ens***^−^**^/+^, 296; *Bsg25D-/Df;ens***^−^**^/+^, 176; *Bsg25D*^−/−^*;BAC, ens*^−/+^ (rescue), 160. **(E)** Viability graph showing survival during development for individuals derived from indicated crosses. The following number of individuals were included for each genotype: *Bsg25D*^−/−^×*Bsg25D*^−/−^*;ens*^−^*/TM6*, 140; *Bsg25D*^−/−^*;ens-/TM6*×*Bsg25D*^−/−^, 153; *Bsg25D*^−/−^*;ens-/TM6*×*wt*, 140; *Bsg25D*^−/−^*;ens*^−/+^×*Bsg25D*^−/−^, 113; *Bsg25D-/Df;ens*^−/+^×*Bsg25D*^−/−^, 148; *Bsg25D*^−/−^*;ens-/TM6*×*Bsg25D*^−/−^*;BAC\[Bsg25D+\]*, 144. F, female; M, male. **(F)** Extended-focus projections of representative stage 16 hemisegments from indicated genotypes. **(G)** Bar graph showing mean nuclear spread and SD. For each genotype, number of hemisegments is *plp*^−/−^, *n* = 47; *plp-/Df*, *n* = 24; *Bsg25D*^−/−^*; plp*^−/−^, *n* = 39; *plp-/+*, *n* = 34; *Bsg25D*^−/−^*;plp-/+*, *n* = 29. P values were calculated by Student's *t* test. The control data in G are the same as in C; for representative image, see first panel in B. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*\*, P \< 0.0001. In all confocal images, red brackets indicate sample nuclear spread measurements. Tropomyosin, green; nuclei, white. Scale bars = 5 µm.](JCB_201808176_Fig2){#fig2}

In agreement with recent reports ([@bib35]; [@bib57]), we found that *Bsg25D* homozygous null mutants (*Bsg25D*^−/−^) lacking maternal and zygotic *Bsg25D* were viable and fertile, with a modest decrease in the frequency of survival to adulthood relative to wild-type controls (70% vs. 96%; Fig. S2 A). A standard larval motility assay revealed moderately impaired muscle function (Fig. S2 B). Using a transgenic reporter that labels myonuclei in a specific set of muscles (i.e., the lateral transverse muscles; [@bib44]), we found that myonuclear positioning in stage 16 *Bsg25D*^−/−^ myotubes was normal ([Fig. 2 B](#fig2){ref-type="fig"}). Thus, *Bsg25D* is not essential for viability, fertility, or myonuclear positioning.

We next considered the possibility that *Bsg25D* plays a role in myonuclear positioning but that the pathway it affects is robust enough to withstand the loss of *Bsg25D* if the other components are present at wild-type levels. To investigate this possibility, we generated double mutants in which *Bsg25D* and candidate interactor genes were targeted. We found that *ens^−/+^* embryos lacking all maternal and zygotic Bsg25D had significantly more impaired myonuclear positioning than *ens^−/+^* embryos containing the normal complement of Bsg25D ([Fig. 2, B--D](#fig2){ref-type="fig"}): at stage 16, *Bsg25D*^−/−^;*ens^−/+^* myonuclear clusters traversed less of the distance toward the muscle poles. Further, in some myotubes, myonuclei are present as one cluster, resembling those found in *ens*^−/−^ homozygotes ([@bib39]). Enhancement of myonuclear positioning defects was also observed when one copy of the null *Bsg25D* allele was replaced by a deficiency removing the gene ([Fig. 2, B--D](#fig2){ref-type="fig"}), which argues that the enhancement effect was specific to the *Bsg25D* region. Moreover, we rescued the *Bsg25D*^−/−^*;ens^−/+^* enhanced phenotype by reintroducing *Bsg25D^+^* from the large genomic Bacterial Artificial Chromosome (BAC) insertion CH321-49G22 ([Fig. 2, B--D](#fig2){ref-type="fig"}). In addition, *Bsg25D*^−/−^*;ens*^−/−^ double mutants showed the *ens*^−/−^ phenotype, which is the most severe clustering phenotype (Fig. S3 A). We conclude that endogenous *Bsg25D* and *ens* likely affect a common pathway that moves myonuclei in embryonic myotubes.

*Bsg25D* and *ens* genetically interact in nonmuscle cells as well, as embryonic lethality occurred when Bsg25D and Ens were jointly removed in a specific genetic combination. Nearly 100% of embryos derived from *Bsg25D*^−/−^;*ens^−^/TM6* mothers and *Bsg25D*^−/−^ fathers failed to hatch ([Fig. 2 E](#fig2){ref-type="fig"}). However, embryos derived from the reciprocal cross survived well ([Fig. 2 E](#fig2){ref-type="fig"}). *Bsg25D*^−/−^;*ens^−^*/*TM6* females crossed with wild-type males laid eggs that hatched, demonstrating that those females are fertile. We also observed widespread death when the third chromosome balancer *TM6* was replaced by a wild-type chromosome, indicating that the genetic interaction was not due to mutations on the balancer chromosome. The phenotype also persisted when one of the *Bsg25D* alleles was replaced with a deficiency completely uncovering *Bsg25D*. Furthermore, restoring *Bsg25D^+^* through a BAC transgene achieved nearly complete rescue ([Fig. 2 E](#fig2){ref-type="fig"}, compare black and salmon-colored lines in graph). We conclude that *Bsg25D* and *ens* are jointly required to support normal embryonic development. Since genotypes with even the strongest myonuclear positioning defects survive embryonic development ([@bib39]), the observed lethality must be due to issues in nonmuscle cells.

To gain further insights to the role of *Bsg25D*, we tested for genetic interactions between *Bsg25D* and other genes involved in myonuclear positioning or MT biology. We did not detect interactions between *Bsg25D* and the genes encoding *Khc* and *Dhc* (which are essential for myonuclear positioning) or *patronin* and the γ-Tubulin homologue *γTub23C* (which interact with *Ninein/noca-1* in *C. elegans* \[[@bib55]\]; Fig. S3, B and C; and data not shown). We also tested *pericentrin-like protein* (*plp*) mutants. Interestingly, *plp*^−/−^ mutants had myonuclear positioning defects; nuclear clusters usually split correctly but failed to move the normal distance toward the muscle poles by stage 16 ([Fig. 2, F and G](#fig2){ref-type="fig"}). The same phenotype was observed when one allele of *plp* was replaced by a deficiency uncovering the gene ([Fig. 2, F and G](#fig2){ref-type="fig"}). However, loss of *Bsg25D* did not further enhance myonuclear positioning defects in either *plp* homozygotes or heterozygotes ([Fig. 2, F and G](#fig2){ref-type="fig"}); thus, although we observed colocalization between the two proteins in myotubes, we did not uncover a role for Bsg25D--Plp interactions in myonuclear positioning. Taken together, these results reveal dosage-sensitive genetic interactions only between *Bsg25D* and *ens*; these are not observed with other genes involved in MT biology or myonuclear positioning.

Muscle-specific overexpression of Bsg25D causes defects in embryonic myonuclear positioning by sequestering Ens {#s05}
---------------------------------------------------------------------------------------------------------------

Having demonstrated that *Bsg25D* functions in myonuclear positioning, we next performed gain-of-function analysis with the Gal4/upstream activating sequence (UAS) system ([@bib7]) using the muscle-specific *Dmef2* promoter to probe the activity of *Bsg25D* in muscle. Strikingly, in stage 16 myotubes overexpressing Bsg25D, myonuclei were present in a single cluster near the myotube center; in contrast, control myotubes at this stage had two nuclear clusters near opposite muscle poles ([Fig. 3 A](#fig3){ref-type="fig"}). This suggests that overexpressed Bsg25D blocked myonuclear cluster separation (stage 14) and movement toward the muscle poles (stages 15 and 16).

![**Overexpressed *Bsg25D* causes nuclear positioning defects in embryonic myotubes by sequestering endogenous Ens. (A)** Extended-focus projections of representative stage 16 hemisegments from indicated genotypes. Green, Tropomyosin; white, nuclei. Red brackets indicate sample nuclear spread measurements. **(B)** Bar graph showing mean nuclear spread and SD. For each genotype, the number of hemisegments is as follows: control, *n* = 22; *Dmef2-Gal4\>UAS-Bsg25D*, *n* = 34; *Dmef2-Gal4\>UAS-ens*, *n* = 47; *Dmef2-Gal4\>UAS-GFP:UAS-Bsg25D*, *n* = 25; *Dmef2-Gal4\>UAS-ens;UAS-Bsg25D*, *n* = 42; *ens*^−/+^, *n* = 37; *rP298-Gal4\>UAS-Bsg25D, n* = 33; *rP298-Gal4\>UAS-Bsg25D;ens*^−/+^, *n* = 37. Control data and the representative image are the same as in [Fig. 2](#fig2){ref-type="fig"}. \*\*\*\*, P \< 0.0001. **(C)** Immunofluorescent antibody staining for Bsg25D and Ens in an embryo overexpressing Bsg25D. Arrows show examples of colocalization. Dashed yellow lines outline a lateral transverse myotube. In the merged image: magenta, Bsg25D; green, Ens; white, colocalization. Images in the bottom row are higher magnification views of boxed regions. **(D)** Representative images of stage 16 VL1 myotubes from indicated genotypes. Each image is a single slice from a confocal stack. Red boxes show where the signal intensity was quantified. **(E)** Graph showing Ens intensity, normalized to actin intensity. Number of myotubes is six for both genotypes, mean ± SD. \*, P \< 0.05. Scale bars = 2 µm (A and C) and 5 µm (D).](JCB_201808176_Fig3){#fig3}

That *Bsg25D* overexpression phenocopied loss of *ens* ([Fig. 3 A](#fig3){ref-type="fig"}; [@bib39]) led us to hypothesize that overexpressed Bsg25D inhibits or sequesters endogenous Ens in myotubes. In support of this hypothesis, we found that Ens overexpression, but not overexpression of a control protein (GFP), could rescue Bsg25D-induced nuclear positioning defects. In fact, embryos overexpressing Bsg25D and Ens had even greater nuclear spread than control embryos ([Fig. 3, A and B](#fig3){ref-type="fig"}). This finding led us to examine the effects of overexpressing Ens in otherwise wild-type embryos. We found that overexpressed Ens caused novel myonuclear positioning defects; nuclear spread was increased and nuclei were often present as individuals rather than as part of clusters ([Fig. 3, A and B](#fig3){ref-type="fig"}). In sum, Ens overexpression and Bsg25D overexpression confer reciprocal phenotypes, and Ens overexpression is epistatic to Bsg25D overexpression.

As further support of our hypothesis that overexpressed Bsg25D inhibits or sequesters endogenous Ens, we detected genetic interactions between overexpressed *Bsg25D* and endogenous *ens*. Both loss of one allele of *ens* and overexpression of *Bsg25D* with *rP298-Gal4*, a muscle-specific driver that produces a lower level of gene expression than *Dmef2-Gal4*, conferred reduced poleward movement of nuclear clusters ([Fig. 3, A and B](#fig3){ref-type="fig"}). However, in *ens*^−/+^ embryos expressing *rP298\>Bsg25D*, a much stronger nuclear positioning phenotype occurred ([Fig. 3, A and B](#fig3){ref-type="fig"}). This implies that Bsg25D affects the same pathway as loss of *ens*.

Finally, in support of our hypothesis, we found that overexpressed Bsg25D alters Ens localization. Like endogenous Bsg25D, overexpressed Bsg25D was present both broadly in the cytoplasm and in bright cytoplasmic puncta ([Fig. 3 C](#fig3){ref-type="fig"}). Ens normally localizes to MTs (Fig. S1 D), but in Bsg25D-overexpressing myotubes, Ens was strongly enriched at sites of Bsg25D accumulation in the cytoplasm ([Fig. 3 C](#fig3){ref-type="fig"}). Outside of Bsg25D^+^ puncta, Ens signal was lower in myotubes overexpressing Bsg25D than in controls overexpressing GFP ([Fig. 3, D and E](#fig3){ref-type="fig"}). This argues that overexpression of Bsg25D reduces the amount of Ens on myotubes. Based on our genetic and imaging analyses, we conclude that overexpressed Bsg25D exerts its effect on myonuclear positioning by regulating Ens activity, at least in part by mislocalizing Ens.

Bsg25D and Ens levels regulate the dynamics of myonuclear positioning {#s06}
---------------------------------------------------------------------

We hypothesized that modulating Bsg25D and Ens levels affects nuclear positioning at stage 16 by disrupting the normal dynamics of myonuclear movement during stage 15, when nuclear clusters normally move toward muscle poles. To address this hypothesis, we performed time-lapse microscopy during stage 15, as done previously ([@bib22]; Videos 1, 2, 3, 4, and 5). We measured the distance from the dorsal-most nucleus to the ventral-most nucleus (nuclear spread) at the beginning and end of the time-lapse series. We divided the difference between the final and initial nuclear spreads for each cell by the time elapsed and defined this quotient as Δ nuclear spread ([Fig. 4 A](#fig4){ref-type="fig"}).

![**Dynamics of myonuclear cluster separation are affected by levels of Bsg25D and Ens. (A)** First and last frames from time-lapse series of myonuclear movement during stage 15 in indicated genotypes. Red brackets show change in nuclear spread over time. In *Bsg25D*^−/−^*;ens*^−/+^ images, green and red brackets show adjacent myotubes undergoing opposite Δ nuclear spreads. All images are extended focus projections of Z-stacks. Nuclei are multicolored. Scale bar = 5 µm. **(B)** Graph showing percentages of myotubes undergoing positive versus negative Δ nuclear spread during stage 15. **(C)** Mean and SD of Δ nuclear spread during stage 15. For each genotype in B and C, the number of myotubes is as follows: control, *n* = 112; *Bsg25D*^−/−^, *n* = 72; *Bsg25D*^−/−^*;ens*^−/+^, *n* = 86; *Dmef2-Gal4\>UAS-ens*, *n* = 85; *Dmef2-Gal4\>UAS-Bsg25D*, *n* = 62. P values were calculated by Student's *t* test. \*\*, P \< 0.01; \*\*\*\*, P \< 0.0001. **(D)** Correlation between stage 15 mean Δ nuclear spread and stage 16 mean nuclear spread in fixed samples. Linear regression line is in gray; *r*^2^ is the coefficient of determination.](JCB_201808176_Fig4){#fig4}

We observed that only 59% of control myotubes exhibited positive Δ nuclear spread over a 1-h period during stage 15. This was initially surprising, because we have previously seen that from stages 14 to 16, nuclear clusters move toward myotube poles ([@bib22]; [@bib39]). Our interpretation is that nuclear clusters move toward the muscle poles unevenly, with periods where the nuclear spread increases and periods where it decreases. Nuclear clusters all eventually arrive near the muscle poles because the net positive (poleward) movement is greater than negative (toward the center of the muscle) movement; however, during relatively short time-lapse recordings, the nuclear spread in individual cells can decrease quite dramatically.

The percentage of myotubes exhibiting positive versus negative Δ nuclear spread varied with genotype ([Fig. 4 B](#fig4){ref-type="fig"}). Embryos with muscle-specific Ens overexpression contained the highest percentage of myotubes with positive Δ nuclear spread (81%) and embryos with muscle-specific Bsg25D overexpression the lowest (21%). In Bsg25D-overexpressing embryos at stage 15, myonuclei were either present in a single cluster or two slightly separated clusters. Negative Δ nuclear spread was due to loosely packed single clusters compacting or barely separated clusters coming back together (for example, [Fig. 4 A](#fig4){ref-type="fig"}). Bsg25D-overexpressing cells exhibiting positive Δ nuclear spread had single nuclear clusters that appeared to separate slightly without dividing into two distinct clusters.

We detected a novel behavior in myonuclei from *Bsg25D*^−/−^*;ens^−^*^/+^ embryos. In some cells, two distinct nuclear clusters migrated a considerable distance toward each other and reformed one cluster. In this genotype, there was high variability in dynamic cluster behavior among myotubes; the SD of Δ nuclear spread was greater in *Bsg25D^−^*^/^*^−^;ens^−^*^/+^ cells than in controls (4.47 µm/h vs. 3.42 µm/h, P = 0.008; [Fig. 4 A](#fig4){ref-type="fig"}).

For each genotype, we averaged Δ nuclear spread for each cell, including both negative and positive values ([Fig. 4 C](#fig4){ref-type="fig"}). We found no statistically significant difference between control and *Bsg25D*^−/−^ mutants. Control, *Bsg25D*^−/−^, and Ens-overexpressing cells had a positive average Δ nuclear spread. *Bsg25D*^−/−^;*ens*^−/+^ and Bsg25D-overexpressing cells had a negative average Δ nuclear spread. Across genotypes, there was a strong correlation (*r* = 0.94) between average Δ nuclear spread at stage 15 and average nuclear spread in fixed embryos at stage 16 ([Fig. 4 D](#fig4){ref-type="fig"}). Thus, the rate of nuclear spreading at stage 15 predicts and likely determines the degree of nuclear spread observed at stage 16.

Bsg25D overexpression causes defects in myonuclear positioning in fully differentiated larval muscle that are rescued by addition of Ens {#s07}
----------------------------------------------------------------------------------------------------------------------------------------

Having characterized the effect of Bsg25D overexpression on embryonic myotubes, we next investigated Bsg25D overexpression in mature myofibers. Myofibers are established in the embryo at stage 17 and continue to grow and function during larval stages. We focused on the third-instar larval stage, a time point when the muscles are amenable to functional analysis and antibody staining ([@bib22]). Using the *Dmef2-Gal4* driver, which becomes active in embryonic muscle and persists through the larval stage, we overexpressed either Bsg25D or GFP (as a control) and measured larval motility as a readout of muscle function. Control larvae outperformed Bsg25D-overexpressing larvae ([Fig. 5 A](#fig5){ref-type="fig"}), indicating that Bsg25D overexpression perturbs muscle function. Animals with muscle-specific overexpression of Bsg25D exhibited decreased survival to adulthood, with peak lethality occurring during the pupal stage ([Fig. 5 B](#fig5){ref-type="fig"}). Moreover, adult survivors were unable to fly, indicating that overexpressed Bsg25D also perturbs muscle function in adults (data not shown).

![**Bsg25D overexpression induces nuclear positioning defects in larval myofibers that can be rescued by Ens. (A)** Larval motility in larvae overexpressing either GFP (control) or Bsg25D in muscle. For *Dmef2-Gal4\>UAS-GFP*, *n* = 30 larvae. For *Dmef2-Gal4\>UAS-Bsg25D*, *n* = 12 larvae. P values were calculated by Student's *t* test. **(B)** Viability graph showing survival during development. *n* = 100 individuals for each genotype. **(C and D)** Representative extended focus projections of stained myofibers and nuclear positioning analyses. Green, phalloidin; white, nuclei. Dashed yellow line outlines individual myofibers. Scale bars = 10 µm. Graphs depict mean and SD for three methods for quantifying myonuclear positioning (see Materials and methods). For each genotype, the same images were analyzed with each method. For *Dmef2-Gal4\>UAS-GFP*, *n* = 40 myofibers. For *Dmef2-Gal4\>UAS-Bsg25D*, *n* = 45. For *Dmef2-Gal4\>UAS-GFP;UAS-Bsg25D*, *n* = 23; *Dmef2-Gal4\>UAS-ens;UAS-Bsg25D*, *n* = 19. *Dmef2-Gal4\>UAS-GFP* data are the same in C and D. P values were calculated by Student's *t* test. \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001.](JCB_201808176_Fig5){#fig5}

After assessing muscle function in Bsg25D-overexpressing larvae, we examined muscle structure. In control larvae with muscle-specific GFP expression, myonuclei were evenly spaced throughout muscle fibers, as expected ([Fig. 5 C](#fig5){ref-type="fig"}). In larvae that had developed with sustained muscle-specific Bsg25D overexpression, however, myonuclei were frequently clustered together ([Fig. 5 C](#fig5){ref-type="fig"}). This phenotype was highly penetrant and robustly quantifiable by three different analyses. First, the average distance between each nucleus and its nearest neighbor was decreased. Second, the average longest stretch of myofiber devoid of myonuclei was increased. Third, the average SD of the distances between sequential nuclei (SD of internuclear distance) within a myofiber was increased, indicating irregular, uneven positioning of nuclei ([Fig. 5 C](#fig5){ref-type="fig"}). Unlike stage 16 myotubes, where Bsg25D-induced myonuclear positioning defects were nearly uniform (i.e., one cluster of myonuclei near the myotube's center), larval muscle fibers overexpressing Bsg25D exhibited nuclear clusters that varied in both nuclear number and position within the fiber ([Figs. 5 C](#fig5){ref-type="fig"} and S4 A). The total number of nuclei present per larval muscle was the same in Bsg25D-overexpressing and control larvae (Fig. S4 B). As with other genotypes affecting myonuclear positioning ([@bib18]), Bsg25D overexpression conferred a decrease in nuclear size (Fig. S4 C).

Since Ens overexpression restored nuclear spread in Bsg25D-overexpressing embryonic myotubes ([Fig. 3, A and B](#fig3){ref-type="fig"}), we hypothesized that "rescued" myotubes would develop into myofibers with normal myonuclear positioning. Indeed, when we overexpressed Ens along with Bsg25D starting in embryonic myotubes, the resulting larval myofibers had nearly normal nuclear positioning; in contrast, control myofibers expressing GFP with Bsg25D had severe nuclear positioning defects ([Fig. 5 D](#fig5){ref-type="fig"}). These two genotypes had the same number of myonuclei per myofiber (Fig. S4 D). From these experiments, we conclude that sustained Ens overexpression rescues nuclear positioning defects in Bsg25D-overexpressing mature muscles.

Overexpressed Bsg25D disrupts MT organization in myofibers {#s08}
----------------------------------------------------------

Since Bsg25D and Ens have been shown to regulate MT organization in other contexts ([@bib40]; [@bib17]; [@bib25]; [@bib48]; [@bib35]; [@bib57]), we hypothesized that Bsg25D--Ens interactions control myonuclear positioning by regulating the muscle MT network. However, we did not observe a difference in the density of the MT network in embryonic myotubes among control, *Bsg25D*^−/−^, *Bsg25D*^−/−^*;ens*^−/+^, and *Bsg25D*-overexpressing genotypes ([Fig. 6, A and B](#fig6){ref-type="fig"}). Using time-lapse microscopy to follow genetically encoded EB1-YFP, a fluorescently tagged MT plus end--binding protein that tracks the growing ends of MTs, we observed that EB1-YFP "comets" moved with the same speed in control and *Bsg25D*^−/−^ myotubes (control: 0.36 ± 0.12 µm/s, *Bsg25D*^−/−^: 0.37 ± 0.11 µm/s; Videos 6 and 7 and [Fig. 6, C and D](#fig6){ref-type="fig"}), indicating that MT polymerization rates were unaffected by complete loss of *Bsg25D.*

![**MT density and dynamics are normal in *Bsg25D*^−/−^ embryonic myotubes. (A)** Representative extended-focus projections of Tropomyosin and α-Tubulin signal in stage 16 lateral transverse myotubes. Green boxes in the top row indicate muscle tips magnified in the second and third rows. Red boxes represent regions where signal intensity was quantified. Scale bar = 1 µm. **(B)** Bar graph showing the mean and SD of the ratio of Tubulin to Tropomyosin signal for indicated genotypes. The number of embryos for each genotype is as follows: control, *n* = 9; *Bsg25D*^−/−^, *n* = 14; *Bsg25D*^−/−^*;ens-/+*, *n* = 11; *Dmef2-Gal4\>UAS-Bsg25D*, *n* = 14. P values were calculated by Student's *t* test. The entire experiment was performed twice with similar results; images and graph are from one replicate. **(C)** Representative EB1-YFP comets for indicated genotypes. Schematic shows that comets run toward myotube tips. Images were generated by merging three frames from a time-lapse series, pseudocolored red (t~1~ = 0 s), cyan (t~2~ = 1.6 s), and yellow (t~3~ = 3.2 s). Scale bar = 0.1 µm. **(D)** Scatter plot showing mean speed ± SD (micrometers per second) of EB1-YFP comets. The number of EB1-YFP comets for each genotype is as follows: control, *n* = 140; *Bsg25D*^−/−^, *n* = 94. P value was calculated by Student's *t* test.](JCB_201808176_Fig6){#fig6}

Next, we examined the effect of Bsg25D levels on the mature MT organization of larval myofibers. Larval myofibers are advantageous for genetic analysis of MT organization because they are larger, more regularly shaped, and possess a more clearly organized MT network than myotubes. In control muscle fibers, as previously observed ([@bib18]; [@bib39]), there were two spatially defined populations of MTs: superficial MTs that emanate from the nuclear envelope of each nucleus, and deeper MTs oriented parallel to the long axis of the fiber. While *Bsg25D* null mutants had normal myonuclear positioning (Fig. S4, E and F) and MT organization ([Fig. 7 A](#fig7){ref-type="fig"}), Bsg25D-overexpressing muscle fibers had severe defects in MT organization ([Fig. 7 A](#fig7){ref-type="fig"}). Longitudinal MTs were present, but nuclear MT arrays were completely absent. Instead, MTs appeared to grow from Bsg25D-positive ectopic MTOCs in the cytoplasm, as determined by the colocalization of Bsg25D with the centers of star-shaped MT asters ([Fig. 7 B](#fig7){ref-type="fig"}). Overexpressed Bsg25D also localized inside myonuclei ([Fig. 7 F](#fig7){ref-type="fig"}), as has been seen with overexpressed human Ninein in cell culture. This cell culture localization was linked to posttranslational SUMO modification of Ninein ([@bib13]), and we observed colocalization of the sole *Drosophila* SUMO protein, SUMO-2, and overexpressed Bsg25D in myonuclei, but not in Bsg25D-positive cytoplasmic puncta (Fig. S5). This is consistent with overexpressed nuclear Bsg25D being sumoylated and raises the possibility that sumoylation is necessary for overexpressed Bsg25D to localize to myonuclei.

![***Bsg25D* overexpression perturbs normal MT organization and forms Ens-positive MTOCs in larval myofibers. (A)** Top: α-Tubulin signal in extended-focus projections of larval myofibers. Bottom: Higher magnification images of nuclear MT arrays. Gray, α-Tubulin; blue, nuclei. Red arrows show myonuclear envelope without MTs. **(B)** Extended-focus projections of Bsg25D and α-Tubulin signal in a cytoplasmic Bsg25D punctum in *Dmef2-Gal4\>UAS-Bsg25D* larval myofiber. Bsg25D, green; α-Tubulin, magenta; colocalization, white. **(C)** Top: Ens signal in extended-focus projections of larval myofibers of indicated genotypes. Bottom: Higher magnification images of nuclei delineated by red boxes. Gray, Ens; blue, nuclei. **(D)** Extended-focus projections of Bsg25D and Ens signal in a cytoplasmic Bsg25D punctum in *Dmef2-Gal4\>UAS-Bsg25D* larval myofiber. Bsg25D, green; Ens, magenta; colocalization, white. **(E)** Staining of larval myofibers with phalloidin (labeling Actin) and an antibody against acetylated Tubulin. Images are single slices from Z-stacks, immediately below myonuclei. Staining for actin confirms the presence of intact myofibers. **(F)** Single slice through a *Dmef2-Gal4\>UAS-Bsg25D* myofiber nucleus. Blue, Hoechst; green, Bsg25D. In all images, scale bars = 10 µm. In B, D, and F, Bsg25D localization is visualized by Eos, which fluorescently tags the N-terminus of overexpressed Bsg25D. **(G)** Left: Frequency histogram of all stiffness measurements from AFM for indicated genotypes. For *Dmef2-Gal4\>UAS-GFP*, *n* = 21 myofibers. For *Dmef2-Gal4\>UAS-Bsg25D*, *n* = 16 myofibers. In each genotype, multiple measurements were taken per myofiber; see materials and methods. P value was calculated by Student's *t* test: \*\*\*\*, P \< 0.0001. Right: Examples of an AFM force map for each genotype.](JCB_201808176_Fig7){#fig7}

Since we have shown that Bsg25D overexpression affects Ens localization in embryonic myotubes ([Fig. 3 C](#fig3){ref-type="fig"}), we next determined how it affects Ens localization in mature myofibers. Immunofluorescent staining in control myofibers showed Ens broadly expressed with increased signal around myonuclei, consistent with Ens (a MAP) being present on MTs ([Fig. 7 C](#fig7){ref-type="fig"}). This localization was not affected by loss of *Bsg25D* ([Fig. 7 C](#fig7){ref-type="fig"}). However, in myofibers overexpressing *Bsg25D*, Ens was lost from nuclear peripheries and instead colocalized with Bsg25D puncta in the cytoplasm ([Fig. 7, C and D](#fig7){ref-type="fig"}). However, Ens did not label the MTs emanating from Bsg25D puncta ([Fig. 7, B](#fig7){ref-type="fig"} vs. D). Thus, when Bsg25D is overexpressed, Ens becomes mislocalized from MTs to cytoplasmic Bsg25D puncta.

To further investigate the Bsg25D-induced disruptions to the MT network in larval myofibers, we performed immunofluorescent antibody staining to detect MTs bearing an acetylation modification associated with MT stability. Control muscles exhibited acetylated MTs emanating from the nuclear envelope, as well as in the deeper longitudinal tracts ([Fig. 7 E](#fig7){ref-type="fig"}). In Bsg25D-overexpressing myofibers, the antibody against acetylated MTs only weakly labeled longitudinal MTs ([Fig. 7 E](#fig7){ref-type="fig"}). This indicates the longitudinal MTs in Bsg25D-overexpressing muscles were hypoacetylated relative to controls. (There was no acetylated tubulin signal around myonuclei, because there were no MTs there.) It was recently shown that MT acetylation in neuronal branches correlates with the subcellular localization of Ens ([@bib54]), raising the possibility that overexpressed Bsg25D causes MT hypoacetylation by sequestering Ens away from MTs. Taken together, Bsg25D overexpression causes defects in MT organization and posttranslational acetylation; the latter may be indicative of a loss of MT stability.

We next investigated whether Bsg25D overexpression affected the mechanical properties of myofibers by performing atomic force microscopy (AFM) to measure stiffness in control (GFP-overexpressing) and Bsg25D-overexpressing myofibers. We found a significant decrease in the stiffness of Bsg25D-overexpressing myofibers (*Dmef2-Gal4\>UAS-GFP* mean ± SD = 5,895 ± 2,646 Pa, *Dmef2-Gal4\>UAS-Bsg25D* mean ± SD = 3,167 ± 1,735 Pa, P \< 0.0001; [Fig. 7 G](#fig7){ref-type="fig"}), perhaps due to the changes in MT organization that we documented, although the role of MTs in regulating myofiber stiffness appears to be complex and variable between systems ([@bib14]; [@bib42]; [@bib34]). Alternatively, other cytoskeletal elements such as actin or myosin, which have been shown to be critical for generating stiffness in skeletal muscle ([@bib14]), may have been disorganized or reduced in these muscles. Together, this series of experiments shows that overexpressed Bsg25D causes defects in the intracellular organization and mechanical properties of larval myofibers.

Discussion {#s09}
==========

Bsg25D functions in myonuclear positioning {#s10}
------------------------------------------

The *Bsg25D* null mutants we generated, like those in two recent reports, are viable and fertile ([@bib35]; [@bib57]). [@bib57] did not detect any mutant abnormalities, whereas [@bib35] observed a decrease in embryonic hatching and partially penetrant mitotic defects. Our null *Bsg25D* mutant has a lower rate of embryonic death than the mutant generated by [@bib35]. The differences between *the* Bsg25D mutant phenotypes generated by different groups likely reflect the sensitivity of *Bsg25D* mutant phenotypes to genetic background. Because our null *Bsg25D* mutant did not have obvious defects, our analysis of *Bsg25D* required other approaches: generation of double mutants and gain-of-function analysis. Through these approaches, we uncovered a role for Bsg25D in myonuclear positioning, where it works with Ens. To our knowledge, Ninein null mice have not been reported; it will be interesting to observe what aspects of Ninein function are conserved in mammals.

Bsg25D and Ens regulate the dynamics of myonuclear movement {#s11}
-----------------------------------------------------------

Our live imaging of stage 15 embryos yielded unexpected insights about the dynamics of myonuclear movement. We initially thought that nuclear clusters separated at stage 14 and then migrated toward their respective poles in a straightforward fashion. However, in all genotypes tested, we observed both myotubes where the nuclear spread increased during our window of observation and myotubes where nuclear spread decreased. These observations argue for a more complex model of myonuclear positioning in which the forces driving nuclear clusters toward muscle poles (for example, Bsg25D and Ens) are opposed by unknown forces driving clusters toward each other. Thus, the relative levels of these opposing forces during stages 14--16 determine myonuclear spread.

Overexpression of Bsg25D affects multiple aspects of muscle organization and function {#s12}
-------------------------------------------------------------------------------------

Gain-of-function analysis revealed that overexpressed Bsg25D has potent activity in embryonic myotubes and mature myofibers. In myotubes it perturbs myonuclear positioning; in myofibers it perturbs myonuclear positioning, MT organization, muscle stiffness, and muscle function. The severity of these phenotypes suggests it is critical for muscle cells to limit the amount of Bsg25D protein present. In overexpression experiments in the ovary, *Bsg25D* localization and activity is regulated by its 3′ UTR ([@bib35]); however, we found that *Bsg25D* overexpression constructs with or without 3′ UTR confer similar phenotypes in myotubes (data not shown), suggesting that the 3′ UTR is not critical to Bsg25D regulation in muscle. Developing muscle presumably employs other mechanisms to limit the levels of Bsg25D.

Unlike in myofibers, Bsg25D overexpression in embryonic myotubes confers no detectable MT defects. Consistent with these observations, overexpressed Bsg25D did not colocalize with α-Tubulin or γ-Tubulin (data not shown). It is unclear how myotubes resist the MT-altering effects of overexpressed Bsg25D that we observed in myofibers and others have observed in other systems ([@bib49]; [@bib35]; [@bib57]); perhaps myotubes lack an essential cofactor necessary for Bsg25D to induce ectopic MTOCs. In general, our data support that MTs in developing myotubes have different behaviors from MTs in myofibers and in other tissues.

While overexpressed Bsg25D does not perturb MTs in embryonic myotubes, does endogenous Bsg25D regulate MT organization? We failed to detect differences in MT density and polymerization rate between control and *Bsg25D*^−/−^ myotubes; this is in contrast to the *C. elegans* larval epidermis, where *Bsg25D/Noca-1* mutants were found to have lower-than-normal MT polymerization rates by an EB1-based assay analogous to ours ([@bib55]). There are two caveats to our conclusion that *Bsg25D* does not function in MT regulation in *Drosophila* myotubes. First, we could not draw conclusions about the number of polymerizing MTs in each genotype because the EB1-YFP signal was weaker in mutant cells than control cells, making the number of traceable EB1-YFP comets an unreliable proxy for the number of polymerizing MTs. Second, it remains possible that MT phenotypes in *Bsg25D*^−/−^ myotubes are masked by a redundantly acting factor. Though our negative data do not definitively rule out a role for endogenous Bsg25D in regulating MTs in muscle, the absence of clear MT phenotypes in *Bsg25D*^−/−^ myotubes and myofibers leads us to favor the conclusion that Bsg25D functions in myonuclear positioning without playing a major role in MT regulation.

Ens and Bsg25D exhibit complex interactions {#s13}
-------------------------------------------

Our work reveals that Bsg25D and Ens work together in myonuclear positioning. It is not clear exactly where in the myotube they interact to promote myonuclear movement. In immunostained embryos, the most conspicuous Bsg25D signal in myotubes is in cytoplasmic puncta, which also stain positive for Ens. However, there is also a broad, low-level Bsg25D signal throughout the cytoplasm that our microscopy techniques cannot further resolve. Given that Ens coats MTs, it is plausible that Bsg25D interacts with Ens broadly on those structures. Indeed, studies have shown Bsg25D/Ninein interacting with the MT network as a cargo ([@bib15]; [@bib41]), and a Bsg25D fragment has been shown to directly bind MTs in vitro ([@bib35]).

In both myotubes and myofibers, co-overexpression of Ens relieves the myonuclear clustering caused by overexpression of Bsg25D. The mechanisms by which Bsg25D and Ens function likely differ between these two developmental stages. In embryonic myotubes, Bsg25D overexpression phenocopies the *ens* mutant phenotype, so inhibition of Ens by high levels of Bsg25D is sufficient to explain the nuclear positioning defects. However, the nuclear positioning phenotypes in mature larval myofibers caused by long-term overexpression of Bsg25D are more severe than those caused by loss of Ens; thus, inhibition of Ens is not a sufficient explanation for the Bsg25D-induced defects. We propose that Bsg25D causes nuclear positioning defects in larval myofibers through the combined effect of multiple mechanisms, including inhibition of Ens, inhibition of other proteins involved in myonuclear positioning such as Dynein, and disruption of MT organization. Co-overexpressed Ens then suppresses at least some of these Bsg25D activities, restoring normal nuclear positioning.

The finding that embryos with reduced maternal/zygotic *ens* and a total absence of *Bsg25D* fail to survive to larval stages demonstrates that critical Bsg25D--Ens interactions occur outside of the muscle as well. Evidence from the literature raises the possibility that they interact in the female germline, as groups have separately reported overlapping localization patterns for Bsg25D and Ens proteins, with both found at the anterior pole of the developing oocyte during midoogenesis ([@bib50]; [@bib35]). Moreover, misexpression of *Bsg25D* and loss of function of *ens* cause common phenotypes: reductions in Dynein and Gurken at the posterior pole and anterior-dorsal corner of the oocyte, respectively, and resulting embryos lacking dorsal appendages ([@bib50]; [@bib35]). Thus, it may be the case that forced expression of Bsg25D binds and disrupts endogenous Ens in the female germline as it does in muscle.

Centrosomal proteins participate in myonuclear movement {#s14}
-------------------------------------------------------

We find that in addition to Bsg25D, a second centrosomal protein, Plp (the *Drosophila* Pericentrin homologue), is involved in myonuclear positioning. The function of centrosomal proteins in muscle, which lacks centrosomes, has been unclear. Our work suggests that a general function of centrosomal proteins in muscle is to position myonuclei. This hypothesis is supported by the recent finding that the centrosomal protein PCM-1 is required for myonuclear positioning in C2C12 myotubes ([@bib19]). These findings underscore the conservation of mechanisms regulating nuclear movement and muscle organization. It is intriguing that although Bsg25D and Plp colocalize in myotubes, and each participates in myonuclear positioning, loss of *Bsg25D* does not enhance myonuclear positioning defects in *plp* mutants. It may be the case that the two proteins ultimately contribute to myonuclear positioning via separate pathways.

Model {#s15}
-----

We propose that endogenous Bsg25D positively regulates Ens in a manner dependent on their physical interaction ([Fig. 8](#fig8){ref-type="fig"}). The critical interaction could either be at Bsg25D--Ens cytoplasmic puncta or on Ens-coated MTs. Bsg25D could conceivably promote Ens activity by affecting its protein levels, subcellular localization, access to binding partners, or posttranslational modification, or by other means. In our model, embryos with the full complement of *ens* have enough Ens activity to withstand loss of the activator Bsg25D without showing diminished myonuclear movement. However, in embryos where Ens activity is limited by loss of one allele of *ens*, loss of Bsg25D further reduces Ens activity and perturbs myonuclear movement.

![**Model of Bsg25D--Ens interactions. (A)** Model of the Bsg25D--Ens interaction in wild-type myotubes. **(B)** Model of the Bsg25D--Ens interaction when Bsg25D is overexpressed. See Discussion for model details. Bsg25D, blue; Ens, yellow; MTs, orange.](JCB_201808176_Fig8){#fig8}

When Bsg25D is present at high concentrations in myotubes, it confers severe nuclear positioning phenotypes through its interactions with Ens ([Fig. 8 B](#fig8){ref-type="fig"}). Overexpressed Bsg25D forms puncta that recruit endogenous Ens away from its normal localization on MTs, leading to a block in Ens-dependent myonuclear movement toward the muscle poles. In myofibers, these Bsg25D- and Ens-positive puncta serve as ectopic MTOCs. MTs are lost from the nuclear envelope, possibly because necessary factors are recruited to the ectopic MTOCs. Nuclei are mispositioned, in part due to altered MT organization, and muscle function is decreased.

Conclusion {#s16}
----------

We have identified *Drosophila* Bsg25D as a novel Ens interactor and shown that it functions with Ens in myonuclear positioning. We have found that overexpressed Bsg25D blocks myonuclear movements in embryonic myotubes and that sustained Bsg25D overexpression disrupts both myonuclear positioning and MT organization in mature larval myofibers; nuclear positioning defects in embryos and larvae are rescued by cooverexpression of Ens. Thus, Bsg25D--Ens interactions are critical for myonuclear positioning and muscle development. The human homologues of the two proteins have important functions that are illustrated by their association with disease; loss of Ninein causes Seckel syndrome ([@bib16]), while high levels of MAP7 are associated with types of colon cancer and leukemia ([@bib5]; [@bib24]). The use of model systems to investigate how gain and loss of Ninein/Bsg25D and Ens/MAP7 affect cells in vivo will lend insights to human health.

Materials and methods {#s17}
=====================

*Drosophila* genetics {#s18}
---------------------

Standard *Drosophila* genetics were performed at 25°C. The following stocks were used: *apterous~ME~-NLS::dsRed* ([@bib44]), *ens^swo^* ([@bib39]), *Df-ens^Δ3277^* ([@bib50]), khc^8^ ([@bib8]), *dhc^4--19^* ([@bib26]), *plp^5^* ([@bib37]), *Dmef2-Gal4* ([@bib43]), *rP298-Gal4* ([@bib38]), *ubiquitin-Gal4\[3xP3-GFP\]* ([@bib2]), *UAS-Ens-HA* ([@bib39]), *UAS-2xEGFP* ([@bib29]), *UAS-EB1-YFP* ([@bib9]), and *patronin^Δ2^* (gift from M. Gonzalez-Gaitan, University of Geneva, Geneva, Switzerland). *w^1118^* (3605), *yw* (1495), *UAS-Rab7.GFP* (42706), UASp-*GFP.Golgi* (30902), *UAS-GFP.KDEL* (9899), *Df(2L)BSC693* (26545), *Df(3L)BSC441* (24945), *hs-FLP, hs-SceI* (25679), *γ-tub23C^A6-2^* (5728), and *γ-tub23C^A14-9^* (7041) were obtained from the Bloomington Drosophila Stock Center. P3-83 containing BAC clone CH321-49G22, referred to in the text as *BAC\[Bsg25D+\]*, was obtained from Genetivision. The following lines were developed for this work (details below): *Bsg25D^null^, UAS-eos::Bsg25D*, and *UAS-ens::EGFP*. *ens^swo^* and *Df-ens^Δ3277^* homozygotes have the same nuclear positioning phenotype at stage 16 (data not shown). The *Df-ens^Δ3277^* allele was used for genetic interaction experiments with Bsg25D overexpression (the three rightmost panels in [Fig. 3 A](#fig3){ref-type="fig"}). All other experiments with *ens* mutants used the *ens^swo^* allele.

Generation of mutant and transgenic *Drosophila* stocks {#s19}
-------------------------------------------------------

*Bsg25D^null^* (referred to in this work as *Bsg25D*^−/−^) flies were generated by accelerated homologous recombination without CRISPR/Cas9 ([@bib2]). Homology arms 5′ and 3′ of *Bsg25D* were PCR amplified and sequentially cloned into pTV^Cherry^ (gift from J.P. Vincent, Francis Crick Institute, London, UK). The following primers, containing the indicated restriction enzyme sites, were used: 5p homology arm: 5p forward NheI, 5′-GATCGCTAGCAGCCATTCGCCTCGCTCTTC-3′; 5p reverse KpnI, 5′-GATCGGTACCGCTGCCGTTCCAATCGATCG-3′; 3p homology arm: 3p forward BglII, 5′-GATCAG-ATCTGACAAACCTGAGGAGGGAGT-3′; 3p reverse AvrII, 5′-GATCCCTAGGCGTAGAAAGGGTAGAAATAT-3′.

The pTV^Cherry^-Bsg25D donor cassette was then randomly integrated in *w^1118^* flies by p-element transformation (Genetic Services, Inc.). Potential transgenic flies were screened for by mini-white expression, and a third chromosome transgenic line was obtained. Following the published accelerated homologous recombination cross scheme ([@bib2]), 14 putative mutant lines were recovered. One was validated as *Bsg25D^null^* by PCR using primers designed to amplify genomic regions specific to either wild-type or mutant chromosomes, followed by sequencing. The *Bsg25D*^−/−^ line used in this study had the mini w+ cassette inserted between bp334 in the Bsg25D 5′ UTR and bp5919 at the beginning of the Bsg25D 3′ UTR based on the published FLYBASE Bsg25D genomic sequence, leading to the removal of all protein coding sequences and, as a result, all protein isoforms ([Fig. 2 A](#fig2){ref-type="fig"}). The following PCR primers were used for mutant verification: wild-type-specific *Bsg25D*: 1537 forward, 5′-ACAATACGGACGAGGACCAG-3′; 3907 reverse, 5′-TTCCTTTGCAGCCTTGAGTT-3′; mutant-specific *Bsg25D* pair 1: 7224 forward, 5′-GAGTTGCTGTTGCTGCAGAG-3′; 11081 reverse, 5′-TTGACCTCAGCGTCGTAGTG-3′; mutant-specific *Bsg25D* pair 2: 7326 forward, 5′-TGAAGATACCCCACCAAACC-3′; 10289 reverse, 5′-GCGCACTCAGCAAAACATTA-3′. Mutant flies were confirmed by Western blotting for Bsg25D multiple times with biological replicates.

*UAS-eos::Bsg25D* (referred to in this paper as *UAS-Bsg25D*) flies were generated as follows: *Eos* was amplified from pME-eos (gift from D. Raible, University of Washington, Seattle, WA) using the following forward and reverse primers containing restriction sites for NotI and XhoI, respectively: F_NotI_eos_NotI, 5′-CACCGCGGCCGCATGAGTGCGATTAAGCCAGACATG-3′; R_XhoI_eos_no_stop_XhoI, 5′-CTCGAGTCGTCTGGCATTGTCAGGCAATCC-3′. The PCR product was cloned into pUAST. Next, *Bsg25D* was amplified from expressed sequence tag clone LD21844 (Drosophila Genome Resource Center \[DGRC\]), corresponding to transcript Bsg25D-PB, and cloned into pUAST-eos in frame with the N-terminal Eos. The following primers, both containing *Kpn*I restriction sites, were used for PCR: F-CACC-KpnI-Bsg25D, 5′-CACCGGTACCATGGAGGTATCCGCCGATCCGTAC-3′; R-KpnI-stop-Bsg25D, 5′-GGTACCCTAAGGCATGCCAGGCAGTCCACC-3′. pUAS-eos::Bsg25D was randomly integrated in w1118 flies by p-element transformation (Genetic Services, Inc.). Potential transgenic flies were selected by mini-white expression. The eos::Bsg25D line was used for all fly studies on overexpressed Bsg25D.

*UAS-ens::EGFP* flies were generated as follows. Full-length *ens* (LD09626; DGRC) was PCR-amplified using the following primers containing EcoRI and BamHI restriction sites, respectively: 5′-GAATTCATGGCGAGTCTTGGGGGCCAACAC-3′ and 5′-GGATCCCAGCAGCGATATATCTTTATTTTCGTG-3′. The PCR product was cloned into pUAST (DGRC) previously modified to contain a C-terminal EGFP tag. pUAS-Ens::EGFP was randomly integrated in w1118 flies by p-element transformation (Best Gene, Inc.), and potential transgenic flies were screened for by mini-white expression.

Protein sequence analysis {#s20}
-------------------------

Bsg25D protein sequence analysis was performed by InterProScan, which identifies domains by scanning protein sequences against predictive models provided by several different databases ([@bib33]). Alignment of Bsg25D to mouse Ninein was done using the Blastp algorithm (National Center for Biotechnology Information).

Viability assays {#s21}
----------------

Viability assays were done at 25°C essentially as previously described ([@bib46]). For comparison of GFP- and Bsg25D-overexpressing flies, embryos were bleached and selected at stage 16. For other viability assays, embryos were selected without bleaching under halocarbon oil at stage 5. In all cases, a minimum of 100 embryos were selected over multiple days. The number of hatched and unhatched embryos was counted, and all first-instar larvae were transferred to a vial with fresh food. The number of pupae and adults that eclosed was assessed. Viability is represented as a percentage of the initial number of embryos.

Fluorescent antibody staining {#s22}
-----------------------------

Embryos were prepared for staining as previously described ([@bib44]). Larvae were dissected and flat mounted in HL3.1 dissecting buffer and fixed for 20 min in formalin. Embryos and larvae were incubated in primary antibody overnight at 4°C or for 1 h at room temperature at the following concentrations: rat anti-Tropomyosin (1:500; Abcam), rabbit anti-DsRed (1:400; Clontech), chicken anti-GFP (1:500; Abcam), mouse anti-α-Tubulin (1:500; Sigma), mouse anti-acetylated α-Tubulin (1:50; Santa Cruz Biotechnology), mouse anti-γ Tubulin clone GTU-88 (1:500; Sigma), guinea pig anti-Bsg25D ([@bib32]; 1:400; gift from E. Lecuyer, Montreal Clinical Research Institute \[IRCM\], Montreal, Canada), rat anti-Ens (1:100; gift from P. Rorth, University of Copenhagen, Copenhagen, Denmark), rabbit anti-Plp (gift from J. Raff, University of Oxford, Oxford, UK), rabbit anti-Arl8 (1:100; Developmental Studies Hybridoma Bank), and mouse anti-SUMO-2 8A2 (1:50; Developmental Studies Hybridoma Bank). Overexpressed eos::Bsg25D was detected either by Bsg25D antibody staining or by Eos signal. For both embryo and larva staining, Alexa Fluor 488--, Alexa Fluor 555--, and Alexa Fluor 647--conjugated secondary antibodies (Invitrogen) were applied 1:400 for 1 h at room temperature. Hoechst and Alexa Fluor-conjugated phalloidin (either Alexa Fluor 488 or Alexa Fluor 555; Life Technologies) were added with the secondary antibody at 1:400 and 1:200, respectively. Samples were mounted in ProLong Gold antifade reagent (Invitrogen).

Fixed sample imaging and analysis {#s23}
---------------------------------

Z-stacks of fixed samples were acquired using a Leica SP5 laser-scanning confocal microscope equipped with the LAS AF software using a 63× 1.4 NA HCX PL Apochromat oil objective and processed in Volocity (Perkin Elmer) or ImageJ (National Institutes of Health). For analysis of nuclear positioning at stage 16, the Line function in ImageJ was used to measure the distances from the dorsal-most nucleus to the dorsal myotube pole, the ventral-most nucleus to the ventral myotube pole, and the total myotube length. "Nuclear spread" was calculated by subtracting the first two values from the third and expressing the difference as a percentage of total myotube length. For statistical purposes, the mean of the four lateral transverse muscles in a hemisegment was considered one sample. Nuclear positioning data were collected from a maximum of four hemisegments (abdominal hemisegments 2--5) per embryo. Embryos were fixed over the course of multiple days and then pooled for staining and analysis. Myonuclear positioning in the ventral longitudinal (VL) 4 muscle of third-instar larvae was also assessed using the Line function in ImageJ. "Nearest neighbor" was defined as the distance between a nucleus and the nearest neighboring nucleus. "Largest gap" refers to the longest stretch of muscle fiber void of myonuclei, and internuclear distance refers to the distance between consecutive myonuclei along the longitudinal muscle axis. All three terms are presented as percentages of muscle length. Statistical analysis of nuclear positioning in larval muscles employed weighted averages to account for different numbers of myofibers analyzed for each larva. *n* refers to the total number of myofibers. MT density was calculated by measuring the intensity of Tubulin and Tropomyosin near the tips of the muscles, essentially as published ([@bib22]). For statistics, the average of Tubulin/Tropomyosin ratios from multiple cells in the same embryo was considered one sample. Student's *t* tests were performed using Prism software or Excel. Analysis of Ens and Phalloidin signal intensities in embryonic VL myotubes were performed in essentially the same fashion from single slices of confocal stacks.

Time-lapse imaging and analysis {#s24}
-------------------------------

Embryos to be subjected to time-lapse imaging of myonuclear movements were prepared as reported previously ([@bib22]). Embryos were bleached for 4 min, rinsed and mounted in halocarbon oil on a custom-made slide with an air-permeable membrane, and covered with a glass coverslip. Time-lapse series of myonuclear movements were acquired on a Zeiss LSM 700 equipped with the ZEN software and using a Plan-Apochromatic 20×/0.8 M27 objective with 1.7× optical zoom. Stacks were acquired every 3 min for 1 h at 25°C. The line function in ImageJ was used to measure distance between clusters. To calculate Δ nuclear spread, the distance from the dorsal-most nucleus to the ventral-most nucleus in a cell at the beginning of the time-lapse series was subtracted from the same parameter at the end of the series. The difference was then divided by time elapsed to yield Δ nuclear spread, measured in micrometers per hour. Student's *t* tests and correlation analysis were performed using Prism software. F-tests were performed in Excel.

Embryos to be used for EB1-YFP analysis were prepared and mounted as above. Time-lapse series of EB1-YFP comets in the tips of stage 16 lateral transverse muscles were acquired on a Leica TCS SP8 confocal microscope at 25°C using the HCX PL APO 63×/1.30 glycerol lens with 40× optical zoom using the Leica proprietary software. Comets were recorded from 19 cells (control) and 26 cells (*Bsg25D*^−/−^). Z-stacks consisted of ∼10 slices with a step size of 400 nm; stacks were acquired without intervals (i.e., nonstop) at a frame rate of ∼23 frames per second for ∼90 s. Time-lapse datasets were deconvolved by a blind deconvolution algorithm in Autoquant X3 software (Media Cybernetics). EB1-YFP comets were manually tracked in three dimensions using Imaris (Bitplane). For each EB1-YFP comet, the displacement distance between its position in the first and last frames of its run was exported and divided by the time elapsed to determine EB1-YFP comet speed. EB1-YFP speed was compared between groups by Student's *t* test.

Cell culture, coimmunoprecipitation, and Western blotting {#s25}
---------------------------------------------------------

For *Drosophila* S2 cell expression studies, pUAS-3xHA::Bsg25D was generated as follows. Full-length *Bsg25D* (LD21844; DGRC) was PCR amplified using the following primers: 5′-CACCATGGAGGTATCCGCGATCCGTAC-3′ and 5′-CTAAGGCATGCCAGGCAGTCCACC-3′. The amplicon was TOPO cloned into pENTR (Life Technologies) and then Gateway cloned using LR Clonase (Life Technologies) into pTHW (DGRC), which contains a UAS followed by an N-terminal 3xHA tag. The generation of pUAS-Ens::EGFP is described above (in Generation of mutant and transgenic *Drosophila* stocks), as the same plasmid was used for transforming flies and driving expression in S2 cells.

Experiments in S2 cells were performed to validate a physical interaction between Ens and Bsg25D detected in a yeast two-hybrid screen previously described ([@bib39]). S2 cells were cultured in Schneider's media plus 10% FBS using standard procedures. Protein expression was achieved by transfecting a plasmid expressing Gal4 from a constitutively active promoter (Ubiquitin-Gal4) along with pUAS-3xHA::Bsg25D and pUAS-Ens-EGFP or pUAS-3xHA::Bsg25D and pUAS-2xEGFP. Transfections used Effectene (QIAGEN). Cells were lysed 2 d after transfection in lysis buffer (150 mM NaCl, 2 mM MgOAc, 20 mM Tris, pH 7.5, 5% glycerol, 0.5% NP-40, 2 mM DTT, and one Complete Mini tab \[Roche\]). Following centrifugation, lysate supernatant was collected and protein concentration was determined by Bradford assay (Bio-Rad). 400 µg lysate was incubated with Protein G-Agarose beads overnight at 4°C using rabbit anti-GFP (Torrey Pines Biolab) or rabbit anti-IgG (Santa Cruz Biotechnology) for mock immunoprecipitation controls. Following incubation, beads were washed four times with lysis buffer and boiled in 4× Laemmli buffer. Proteins released from beads and 40 µg (10%) inputs were then subjected to SDS-PAGE, transferred overnight to polyvinylidene difluoride membrane, and blotted with rat anti-HA (Roche), secondary stained at 1:5,000 with anti-rat HRP (Jackson ImmunoResearch), and detected with chemiluminescence (Denville Scientific). Membranes were then stripped according to standard practices and reblotted with mouse anti-GFP antibody (Roche) and HRP-conjugated anti-mouse secondary antibody (Jackson ImmunoResearch) and then developed. Coimmunoprecipitation between 3xHA::Bsg25D and Ens-GFP was demonstrated with multiple biological replicates.

To compare Bsg25D protein expression in control and *Bsg25D*^−/−^ genotypes, *w^1118^* and *Bsg25D*^−/−^ third-instar larvae were dissected in HL3.1 relaxing buffer. The intestines of the larvae were removed, and the resultant pelts were lysed in lysis buffer (recipe above). Following Bradford determination of protein concentration (Bio-Rad), 80 µg lysate per genotype was loaded on a 7.5% SDS-PAGE protein gel. The gel was transferred to nitrocellulose membrane overnight, blocked with 5% milk (for Bsg25D) or 5% BSA (for GAPDH) in TBS-Tween, and blotted overnight with guinea pig anti-Bsg25D antibody (1:1,000; gift from E. Lecuyer) or mouse anti-GAPDH primary antibody (1:10,000; Abcam). HRP-conjugated secondary antibodies against guinea pig (1:5,000; Jackson ImmunoResearch) or mouse (1:5,000; Jackson ImmunoResearch) were applied before development by chemiluminescence (Kindle Biosciences).

AFM {#s26}
---

Larvae were dissected in HL3.1 dissecting buffer and fixed in formalin for 10 min before microscopy. Bright-field images of *Drosophila* larvae, for determination of location of stiffness measurements, were acquired using an inverted microscope (Axio Observer Z1; Zeiss) as the AFM base (LD Plan-Neofluar 20×/0.4 objective). An Asylum Research MFP-3D-BIO Atomic Force Microscope was used to collect force maps from the *Drosophila* larvae tissue. A CP CONT-PS-C (NanoAndMore.com) probe with a 6.1-µm polystyrene bead was used for all measurements. The Asylum Research GetReal calibration method was used for the determination of the spring constant (0.2 N/m). Each force map sampled a 20 × 20-µm to 40 × 40-µm region, depending on muscle width, in a 10 × 10-grid under fluid conditions (PBS). The trigger point was set to 50 nN with an approach velocity of 10 µm/s. The force-indentation curves were fit to the Hertz model for spherical tips using Asylum Research Software to determine the Young's modulus, with an assumed Poisson's ratio value of 0.45 for the sample ([@bib12]). For each genotype, at least three larvae were used; from each larva, at least 400 individual measurements, corresponding to four different muscles, were taken. Force maps of stiffness along with individual stiffness values for each measured point were then exported from Asylum Research Software for analysis. For statistics, the average of all the measurements from a single muscle was considered one sample.

Larval motility assays {#s27}
----------------------

Laval motility assays were performed essentially as previously described, either by using a charge-coupled device camera and Ethovision software (Noldus) to record third-instar larvae crawling and automatically calculate crawling speed ([@bib39]) or by placing larvae at the center of an apple juice plate surrounded by zones defined by concentric circles and observing which zone they reached in 30 s of crawling at 25°C ([@bib20]). A minimum of 47 larvae per genotype were used. In all cases, data were acquired over multiple days. P values were calculated by Student's *t* test.

Online supplemental material {#s28}
----------------------------

Fig. S1 shows the subcellular localization of Bsg25D puncta in developing myotubes. Fig. S2 shows *Bsg25D*^−/−^ viability and larval motility data. Fig.S3 shows myonuclear positioning in *Bsg25D*^−/−^*;ens*^−/−^ myotubes and the lack of genetic interactions between *Bsg25D* and *Khc* or *Dhc*. Fig. S4 shows the effects of Bsg25D overexpression on myonuclear clusters. Fig. S5 shows that overexpressed Bsg25D colocalizes with SUMO-2 in myonuclei. Videos show nuclear movements in control (Video 1), *Bsg25D*^−/−^ (Video 2), *Bsg25D*^−/−^*;ens*^−/+^ (Video 3), Bsg25D overexpression (Video 4), and Ens overexpression (Video 5). Videos 6 and 7 show control and *Bsg25D*^−/−^ EB1-YFP comets, respectively.
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